Searchable abstracts of presentations at key conferences in endocrinology

ea0029p76 | Adrenal cortex | ICEECE2012

Dosing regimens for glucocorticoid replacement therapy - a worldwide patient survey

Forss M. , Batcheller G. , Skrtic S. , Johannsson G.

There is no consensus on the best dosing regimen for glucocorticoid replacement therapy. The general intention is to individualize according to the clinical response and use the lowest possible maintenance dose without risking adrenal crisis.Aim: To survey patients with adrenal insufficiency (AI) on their glucocorticoid replacement therapy dosing regimen.Method: Patients (children and adults) were recruited via patient organization...

ea0029p90 | Adrenal cortex | ICEECE2012

Primary aldosteronism during 2007–2011 in Iceland

Jonsdottir G. , Gudmundsson J. , Birgisson G. , Sigurjonsdottir H.

Introduction: Recent publications regarding primary aldosteronism (PA) have challenged the concept of PA being a rare disease. In 2007 a standardized protocol for diagnosing and treating PA was introduced in Iceland for patients suspected of having PA. Data from the Icelandic Heart Association suggests that 35–40% of the adult population (age 46–67) have hypertension. The aim of this study was to gather information about PA as a cause of hypertension at the referral ...

ea0029p795 | Endocrine tumours and neoplasia | ICEECE2012

A novel mutation of the MEN1 gene in an Italian family with Multiple endocrine Neoplasia type 1

Sciortino G. , Vitale G. , Guizzardi F. , Persani L.

Introduction: MEN-1 is a rare autosomal dominant familial cancer syndrome characterized by involvement of parathyroid glands, enteropancreatic endocrine tissues and anterior pituitary gland. This disease is linked to germline mutations in the MEN1 gene (more than 460 described), whose identification allows the familial genetic counselling. Here we describe a novel germinal mutation in exon 10 of the MEN1 gene identified in an Italian family.Case Report: ...

ea0026oc4.6 | Diabetes/Thyroid | ECE2011

No causal relationship between Yersinia enterocolitica infection and autoimmune thyroid disease: evidence from a prospective study

Effraimidis G , Tijssen J G P , Wiersinga W M

Objective: To evaluate prospectively the relationship between Yersinia Enterocolitica (YE) infection and the development of overt autoimmune hypo- or hyperthyroidism (study A) and the de novo occurrence of thyroid antibodies (study B).Subjects and methods: Prospective cohort study of 790 euthyroid women who were 1st or 2nd degree relatives of AITD patients. Follow-up was 5 years, with annual assessments.Study A. Nested case&...

ea0026p368 | Signal transduction | ECE2011

Research resource for analysing functional data of glycoprotein hormone receptors: novel tools to gain deeper insights into molecular mechanisms

Kreuchwig A , Kleinau G , Kreuchwig F , Worth C L , Krause G

The sequence–structure–function-analysis of glycoprotein hormone receptors (SSFA-GPHR) database provides a comprehensive set of mutation data for the glycoprotein hormone receptors (covering the lutropin – (LHCGR), the follitropin (FSHR) and the thyrotropin receptor (TSHR)). Numerous databases present functional information along with pooled data from various public resources, but tools to analyse the molecular effects of genetic variations are as yet poorly pro...

ea0026p716 | Diabetes (epidemiology, pathophysiology) | ECE2011

Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes

Boyanov M , Boneva J , Bakalov D , Sheinkova G , Prodanova G

Introduction: Non-alcoholic fatty liver disease (NAFLD) is a key component of the insulin resistance, the metabolic syndrome and type 2 diabetes mellitus (DM2). The aim was to study the prevalence of NAFLD in women and men with DM2.Methods/design: This is a retrospective, cross-sectional, observational study. We analyzed data from in-hospital patients: 96 women (mean age 63.2±11.4 years) and 80 men with DM2 (mean age 59.0±10.7 years)). Body wei...

ea0019p185 | Endocrine tumours and neoplasia | SFEBES2009

The KL (klotho) gene is epigenetically silenced in primary hyperparathyroid tumours

Bjorklund P , Krajisnik T , AEkerstrom G , Larsson T , Westin G

Background: Klotho was first identified as a gene involved in aging. A recent publication identified klotho as a possible tumour suppressor in breast cancer. We have previously reported decreased expression of klotho in tumours of primary hyperparathyroidism, here we have investigated whether klotho expression is silenced by CpG methylation of the promoter region.Materials and methods: Methylation status of klotho was determined by MSP in 40 parathyroid ...

ea0017p11 | (1) | BSPED2008

GH treatment and quality of life: the practicalities of running a multi-centre research study

Wales G , Bailey L , Eiser C , Wright N , Butler G

Background: The National Institute for Clinical Excellence (NICE, 2002) suggests that measurement of quality of life (QOL) is necessary to assess the efficacy of GH treatment (GHT). A pilot study (Sheppard 2006) showed a greater improvement in QOL over the first 6 months of GHT for patients with acquired GH deficiency (AGHD) compared with idiopathic GH deficiency (IGHD).Method: In view of this, a longitudinal research study was set up to measure changes ...

ea0016p259 | Diabetes and cardiovascular diseases | ECE2008

Obestatin inhibits high glucose-induced reactive oxygen species production and apoptosis in bovine aortic endothelial cells

Arnoletti E , Granata R , Alloatti G , Ghigo E , Muccioli G

Endothelial dysfunction is thought to be a major cause of vascular complications in diabetes. Our research shows that obestatin, a 23-aminoacid amidated peptide recently identified as a product of the ghrelin gene, inhibited high glucose-induced apoptosis in cultured bovine aortic endothelial cells (BAEC). Exposure to high glucose concentration (30 mM) for 72 h caused a significant increase in apoptosis, as evaluated by Hoechst staining, but co-treatment of rat obestatin (from...

ea0011p842 | Thyroid | ECE2006

Differential regulation of soluble Fas in patients with autoimmune thyroid disease

Fountoulakis S , Kolaitis N , Philippou G , Vartholomatos G , Tsatsoulis A

Introduction-objective: Fas-mediated thyroid cell apoptosis is differentially regulated in autoimmune thyroid disease (AITD) being up-regulated in Hashimoto’s thyroiditis (HT) and down-regulated in Graves’ disease (GD). The soluble form of Fas (sFas), lacking the transmembrane domain due to alternative splicing may inhibit apoptosis by binding to Fas ligand. In this preliminary study we examined whether sFas is also differentially expressed in patients with AITD....